The Trait Is Not the Asset Any More. The Approval Is.

Two hundred and thirty-nine approvals, and one company inside sixty per cent of them

The most valuable asset in the genetically modified seed business is no longer the event. It is the line on a regulator’s list that says the event may be planted. Everything the industry measures — market share, royalty rate, the price of a bag — is downstream of that line, and the difficulty of getting one is why the structure of the market looks the way it does.

The evidence is Chinese, because China is where the list is being written fastest. By the fourth batch in late 2026 China had approved 239 GM varieties — 219 maize and 20 soybean — and Beijing Dabeinong disclosed that its events sit inside 133 of the 219 maize varieties, a 60.73% share of the national approval list. In the world’s fastest-expanding GM market, one company’s genetics are inside three of every five varieties a farmer is legally permitted to buy.

That is the number worth arguing about, and it is why this piece is about the approval rather than the trait. A trait that cannot be planted in a jurisdiction is worth nothing there; a trait with a place on the list is worth a royalty in every bag it appears in.

What a working approval system looks like

China’s move from pilot to routine commercial planting took three seasons and is worth reading as a case study in how a market is created by a regulator rather than by a breeder. The 2024 demonstration programme covered eight provinces and roughly 1.07 million mu. In 2025 it extended to thirteen provinces and passed 30 million mu. The 2026 season is the first conducted under ordinary commercial planting rules, with maize targeted at 57.85 million mu and soybean at 1.03 million mu across 23 provinces plus the Xinjiang Corps and Beidahuang.

That puts GM maize at close to 9% of a national maize seed area of about 650 million mu — from a standing start in three years. The field results are the reason the policy held: efficacy above 90% against fall armyworm and stem borer, average yield gains of 8.5%, and a cost-and-revenue benefit of RMB 132.5 per mu in maize. In the 2025 season Chinese GM area grew 79.0%, and the country added 2.7 million hectares in a single year.

The other side of the same calendar

Europe is the counter-example, and it is not a story about science. It is a story about time. The GM and biotech seed market is USD 26.15 billion in 2025, rising to USD 41.37 billion by 2033. Europe is USD 0.15 billion of it — 0.6%.

Regulation (EU) 2026/1388 was adopted on 17 June 2026, entered into force on 16 July 2026, and applies from 17 July 2028. It creates a category 1 route for edited plants meeting defined equivalence criteria, treated broadly like conventionally bred plants, and leaves category 2 plants inside the GMO regime with adaptations. Until July 2028 the existing GMO rules apply to all new genomic techniques, and no crop developed exclusively through NGTs is yet authorised for food or feed in the EU.

Read those two paragraphs together and the commercial consequence is stark. China moved from a 1.07 million mu demonstration to a 57.85 million mu national target in three seasons. Europe has legislated a pathway and scheduled it to begin in 2028. Between those two calendars sits the entire difference between a 0.6% share of a USD 26.15 billion market and a 9% share of a 650 million mu one.

The licensing turn

The licensing shift is the market’s own verdict on where the asset sits. In early 2026 Corteva settled all litigation with Bayer for a USD 610 million cash outflow, pulled its royalty-neutrality target forward two years to 2026, and set out to become a net out-licensor of seed technology. The settlement brought forward the availability of triple-stack maize traits for out-licensing by roughly five years, to as early as 2027, and advanced third-generation above-ground insect traits by about two years.

What that does is separate two businesses that were previously one. The owners of the events concentrate; the sellers of seed widen. Licensed and out-licensed technology rises from 32.7% of market value to 35.0% by 2033, which is a small percentage move on a large number — USD 14.48 billion of a USD 41.37 billion market passing through a licence rather than a brand. Below the top four, the independent seed sector becomes viable in a way it was not when selling GM seed required a full alliance with a trait owner.

Why the next approval matters more than the next discovery

Gene-edited and NGT-derived seed is 1.3% of 2025 value and the fastest-growing segment in the forecast at 16.3% a year. It is also the clearest illustration of the argument. The technology’s commercial value is contingent entirely on category 1 verification capacity in the EU and on equivalent determinations in Japan, Brazil, Argentina, Canada, the Philippines and Colombia. A pipeline of edited events that no jurisdiction will classify is worth the cost of the research and nothing else.

That is why the industry’s competitive frontier has moved from the laboratory to the docket, and why the numbers that matter are counts of approved varieties rather than counts of patents. Thirty countries cultivate GM crops today; 239 varieties are approved in one of them; one company holds a 60.73% position across that list. The trait is the input. The approval is the asset.

Note on scope: this article was planned as an argument that the cost of a single trait approval now exceeds the cost of the trait. That claim cannot be substantiated from this cluster’s dataset — regulatory cost per event is not disclosed consistently enough to publish a figure. What is measurable is the timeline and the approval count, and the argument above is built on those instead.

Sources and editorial references. The approval-count and calendar figures in this piece derive from our GM and biotech seeds report and the primary sources behind it: China’s Ministry of Agriculture and Rural Affairs for announcements 732, 830, 947 and 1072 and the transformation-event counts; EUR-Lex for Regulation (EU) 2026/1388 and its 17 July 2028 application date; and ISAAA for event approvals elsewhere. Regulatory cost per event is not disclosed consistently and is not asserted in this piece.